Statin Dosing Recommendations
For most patients requiring statin therapy, start with moderate-intensity statins (atorvastatin 10-20 mg or rosuvastatin 5-10 mg daily), and use high-intensity statins (atorvastatin 40-80 mg or rosuvastatin 20-40 mg daily) for patients with established atherosclerotic cardiovascular disease or those at very high risk.
Statin Intensity Categories and Specific Doses
The most recent ACC/AHA guidelines 1, 2 categorize statins by their expected LDL-C reduction:
High-Intensity Statins (≥50% LDL-C reduction):
- Atorvastatin 40-80 mg daily
- Rosuvastatin 20-40 mg daily
Moderate-Intensity Statins (30-49% LDL-C reduction):
- Atorvastatin 10-20 mg daily
- Rosuvastatin 5-10 mg daily
- Simvastatin 20-40 mg daily
- Pravastatin 40-80 mg daily
- Lovastatin 40 mg daily
- Fluvastatin XL 80 mg daily
- Pitavastatin 2-4 mg daily
Low-Intensity Statins (<30% LDL-C reduction):
- Simvastatin 10 mg daily
- Pravastatin 10-20 mg daily
- Lovastatin 20 mg daily
- Fluvastatin 20-40 mg daily
- Pitavastatin 1 mg daily
Clinical Application by Patient Population
Primary Prevention (No ASCVD):
Ages 40-75 years with diabetes: Use moderate-intensity statin therapy 3. Consider high-intensity therapy if multiple ASCVD risk factors present or ages 50-70 years 3.
Ages 40-75 years without diabetes: Use moderate-intensity statin for 10-year ASCVD risk ≥7.5% 2. High-intensity may be reasonable for risk ≥20% 3.
Ages 20-39 years: Initiate statin therapy only if additional ASCVD risk factors present (consider moderate-intensity) 3.
Secondary Prevention (Established ASCVD):
All patients with ASCVD: High-intensity statin therapy is the standard 1, 3, 4. The 2025 ACC/AHA ACS guidelines specifically recommend simvastatin 40 mg (as used in IMPROVE-IT trial) or equivalent high-intensity alternatives 1.
Very high-risk ASCVD patients: If LDL-C remains ≥70 mg/dL on maximally tolerated statin, add ezetimibe or consider PCSK9 inhibitor 3.
Severe Hypercholesterolemia (LDL-C ≥190 mg/dL):
Start with maximally tolerated statin therapy (typically high-intensity) 2, 5. If <50% LDL-C reduction achieved or LDL-C remains ≥100 mg/dL, add ezetimibe 2, 5.
Special Populations
Chronic Kidney Disease:
Most statins require no dose adjustment for mild-to-moderate kidney disease 6:
- Atorvastatin, pravastatin: No adjustment needed
- Rosuvastatin: Start 5 mg daily if CrCl <30 mL/min, maximum 10 mg daily 6
- Simvastatin: Start 5 mg daily in severe kidney disease 6
- Lovastatin: Use doses >20 mg cautiously if CrCl <30 mL/min 6
Elderly Patients (>75 years):
Continue statin if already tolerating 3, 7, 3. For new initiation, use moderate-intensity therapy with careful monitoring 3. Start at lower doses and titrate gradually given altered pharmacokinetics 7.
Critical Dosing Principles
Avoid simvastatin 80 mg: The FDA warns against initiating or titrating to simvastatin 80 mg due to increased myopathy risk 2. Maximum recommended dose is 40 mg daily.
Statin intolerance management: If patients cannot tolerate intended intensity, use the maximally tolerated dose 1, 3. Consider trying at least 2 different statins, including one at the lowest approved dose, before declaring intolerance 1.
Monitoring: Check lipid panel 4-12 weeks after initiation or dose change, then annually 3. The highly variable individual response to statins necessitates post-treatment measurement 8.
Common Pitfalls
Underdosing in secondary prevention: Many patients with established ASCVD receive moderate-intensity when high-intensity is indicated. The 2025 ACS guidelines emphasize early initiation of high-intensity therapy 1.
Ignoring baseline LDL-C: While fixed-dose approaches are recommended, patients with very high baseline LDL-C may benefit from initial higher doses or early addition of ezetimibe 8, 9.
Premature discontinuation: Even extremely low, less-than-daily doses provide benefit 3. Attempt dose reduction or alternative statins before stopping entirely.